

Labetuzumab govitecan (Synonyms: ANTI-CEACAM5-SN 38)



Catalog Number: 177173

Product name

Labetuzumab govitecan (Synonyms: ANTI-CEACAM5-SN 38)

Specificity

Human CEACAM5 / CEA / CD66e

Antibody description

Anti-CEACAM5 / CEA / CD66e Antibody (Labetuzumab govitecan)

Preparation

Recombinant expression and purified from CHO cells.

Formulation

0.1 M Pro-Ac, 20 mM Arg, pH 5.0

Storage

-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.

Clonality

Monoclonal


Ig Type

IgG1

Applications


ELISA

Validations




SEC-HPLC

The purity of Anti-CEACAM5 / CEA / CD66e Antibody (labetuzumab govitecan) is 95%, determined by SEC-HPLC.



HIC-HPLC

The drug-to-antibody ratio (DAR) of the Anti-CEACAM5 / CEA / CD66e Antibody (labetuzumab govitecan) is 8.0.



Bioactivity: FACS

Human CEACAM5 / CEA / CD66e HEK293 Cell Line were stained Anti-CEACAM5 / CEA / CD66e Antibody (labetuzumab govitecan) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 1.45 µg/mL.